Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Prostate Cancer

    EU PROSTATE CANCER PARTNER

    World Prostate Cancer Partner

    An Introduction to Prostate Cancer

    The management of prostate cancer has evolved rapidly over the last decade. There are now several approved treatments in the castration-resistant treatment setting, delivering significant benefits like overall survival rate. The androgen receptor-targeting agents are also now proving effective in the hormone-sensitive setting.

    Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Prostate Cancer Content

    Prostate Cancer
    Redefining Treatment Paradigms in Metastatic Castration-resistant Prostate Cancer: A Comprehensive Analysis of Cabozantinib and Atezolizumab Based on the CONTACT-02 Study Results
    Sara Elyas, Ulka Vaishampayan

    touchREVIEWS in Oncology & Haematology. 2024;20(2):Online ahead of journal publication

    Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into various stages, from early stage to metastatic castration-resistant, each presenting unique clinical challenges. Notably, metastatic […]

    Genitourinary Cancer, Prostate Cancer
    Is prostate cancer overdiagnosis a risk in Europe’s screening efforts?

    A recent study examining prostate cancer trends across 26 European countries has provided vital data for the ongoing discussions around implementing EU-wide screening programs.

    Genitourinary Cancer, Prostate Cancer, Radiology
    New study shows combined power of deep learning and radiologists in prostate cancer detection

    A new study published in the Journal of Radiology reveals promising advancements in the use of artificial intelligence (AI) to improve radiology reporting, particularly in the context of prostate cancer detection. The research demonstrates that AI can significantly enhance the accuracy and efficiency of radiological assessments, especially in complex cases involving large sets of imaging data.

    Prostate Cancer, Genitourinary Cancer, Radiotherapy
    Watch Time: 49 mins
    touchCONGRESS
    PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
    CE/CME ACCREDITED Prof. Oliver Sartor, Prof. Francesco Ceci, Dr Heather Jacene Translations available:

    Three experts discuss data presented at ESMO 2023 on PSMA-targeted radiopharmaceuticals in prostate cancer.

    Learning objectives
    Learning Objectives
    • Describe potential strategies to refine selection of patients with advanced prostate cancer for treatment with PSMA-targeting radiopharmaceuticals
    • Outline how the latest data for PSMA-targeting radiopharmaceuticals may impact the timing of their use in patients with advanced prostate cancer
    • Analyse the latest data on radiopharmaceuticals in advanced prostate cancer, including combination strategies and novel agents in clinical development
    Prostate Cancer
    Developed by Touch
    ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
    Watch Time: 7 mins

    The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]

    Prostate Cancer
    Watch Time: 31 mins
    touchEXPERT OPINIONS
    Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
    CE/CME ACCREDITED Dr Tanya Dorff, Ms Brenda Martone, Dr Stephen Freedland

    Watch three experts discuss the risks and benefits of ADT, the barriers to equitable care and how to improve treatment adherence in prostate cancer.

    Learning objectives
    Learning Objectives
    • Review the risks and benefits of gonadotropin-releasing hormone agonists and antagonists in the treatment of advanced prostate cancer
    • Discuss strategies to promote equitable care and address disparities in prostate cancer treatment outcomes
    • Evaluate ways to incorporate patient preferences and improve adherence to ADT in clinical practice
    Prostate Cancer
    Developed by Touch
    Arnulf Stenzl: Highlights from EAU23!
    Watch Time: 7 mins

    touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]

    Genitourinary Cancer, Prostate Cancer
    Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
    Watch Time: 3 mins

    Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]

    Genitourinary Cancer, Prostate Cancer
    Developed by Touch
    Axel Merseburger: Highlights of EAU23
    Watch Time: 5 mins

    Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup